Dermata Therapeutics (DRMA) Q1 2026 earnings summary

Executive summary

• Strategic pivot in September 2025 from prescription dermatology to direct-to-consumer (DTC) skincare, launching the Tome brand with first product debut planned for mid-2026.

• Focus on leveraging clinical dermatology expertise to create science-backed, consumer-friendly skincare products using Spongilla lacustris as a key ingredient.

• New leadership in marketing brought on to support DTC strategy.

• No revenue generated to date; operations funded primarily through equity offerings.

Financial highlights

• Net loss for Q1 2026 was $1.85 million, an improvement from $2.30 million in Q1 2025.

• Cash and cash equivalents totaled $6.9 million as of March 31, 2026, down from $7.5 million at year-end 2025.

• Operating expenses decreased to $1.93 million in Q1 2026 from $2.34 million in Q1 2025.

• Research and development expenses fell to $0.4 million from $1.3 million year-over-year due to completion of clinical trials and strategic shift.

• Selling, general and administrative expenses increased to $1.5 million from $1.1 million year-over-year, mainly due to higher marketing and legal costs.

• Interest income increased to $78,676 in Q1 2026 from $36,216 in Q1 2025.

Outlook and guidance

• Cash runway expected to fund operations into Q1 2027; additional capital likely needed for continued commercialization and growth.

• Anticipates continued net losses for at least the next twelve months.

• First DTC product launch targeted for mid-2026, with future product line expansions planned.